Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 1/2 1

Status

Completed 8Recruiting 4Withdrawn 2Unknown 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Leukemia, Myeloid, Acute 19Breast Neoplasms 17Advanced Solid Tumors 16Advanced Solid Tumor 12Carcinoma, Non-Small-Cell Lung 10Myelodysplastic Syndromes 9Uterine Cervical Neoplasms 6Solid Tumor 6Recurrence 6Prostatic Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Triple Negative Breast Neoplasms 5Stomach Neoplasms 5Ovarian Neoplasms 5Carcinoma, Hepatocellular 5Small Cell Lung Carcinoma 4Myeloproliferative Disorders 4Multiple Myeloma 4Advanced Solid Tumour 4Advanced Malignant Solid Tumor 4Solid Tumors 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Myelomonocytic, Chronic 3Biliary Tract Neoplasms 3Advanced Lung Cancer 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2

Interventions

Dexamethasone 87daratumumab 49Lenalidomide 49pomalidomide 33Bortezomib 32Cyclophosphamide 31carfilzomib 25Calcium Dobesilate 21talquetamab 19fludarabine 18isatuximab 16iberdomide 16Magnetic Resonance Spectroscopy 16Specimen Handling 15Biopsy 14selinexor 12Melphalan 11belantamab mafodotin 10dexamethasone acetate 9dexamethasone 21-phosphate 8elotuzumab 7auricularum 7venetoclax 6tocilizumab 5fludarabine phosphate 5X-Rays 5Blood Specimen Collection 5ruxolitinib 4Methylprednisolone 4Injections 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Multiple Myeloma × Injections × Clear all
NCT05020236 2026-05-05

MAGNETISMM-5

Pfizer

Phase 3 Recruiting
944 enrolled
Plasma cell

Multiple Myeloma

NCT06484777 2026-04-16

A Clinical Study of SHR-9539 in Patients With Multiple Myeloma

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1 Recruiting
138 enrolled
Plasma cell

Multiple Myeloma

NCT06574568 2026-02-05

A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma

Excyte Biopharma Ltd

Phase 1 Recruiting
70 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT06049290 2025-12-04

A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma

Nanjing Leads Biolabs Co.,Ltd

Phase 1/2 Recruiting
342 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡